SCHEMBL3377314

SCHEMBL3377314

CN(Cc1ccccc1)C[C@H]1C[C@@H](O)C1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
LMNA P02545 2/20 0.46
BLM P54132 1/20 0.46
KDM4E B2RXH2 2/20 0.45
CARM1 Q86X55 1/20 0.44
PRMT6 Q96LA8 1/20 0.44
PRMT8 Q9NR22 1/20 0.44
SLC18A3 Q16572 1/20 0.44
TSHR P16473 2/20 0.44
USP2 O75604 1/20 0.43
CYP3A4 P08684 1/20 0.43
MAOA P21397 1/20 0.43
MAOB P27338 1/20 0.43
PYCR1 P32322 1/20 0.43
CXCR3 P49682 1/20 0.41
AOC3 Q16853 1/20 0.41
SIGMAR1 Q99720 1/20 0.41
GAA P10253 1/20 0.41
MAPT P10636 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3377311 1.00 ALDH1A1 (0.46) ALDH1A1SMN1; SMN2LMNABLMKDM4E
SCHEMBL31716232 0.83 CARM1 (0.49) ALDH1A1SMN1; SMN2LMNABLMKDM4E
SCHEMBL7768827 0.83 ALDH1A1 (0.46) ALDH1A1SMN1; SMN2LMNABLMKDM4E
SCHEMBL25306597 0.82 KDM4E (0.48) ALDH1A1KDM4ESLC18A3TSHRMAPT
SCHEMBL14045705 0.82 ALDH1A1 (0.52) ALDH1A1SMN1; SMN2LMNABLMKDM4E
SCHEMBL522763 0.77 SLC18A3 (0.49) ALDH1A1SMN1; SMN2LMNABLMCARM1
SCHEMBL31715959 0.76 SMN1; SMN2 (0.43) ALDH1A1SMN1; SMN2KDM4ECARM1PRMT6
SCHEMBL8283980 0.76 ALDH1A1 (0.46) ALDH1A1SMN1; SMN2LMNABLMKDM4E
SCHEMBL19715652 0.75 ALDH1A1 (0.49) ALDH1A1SMN1; SMN2LMNABLMKDM4E
Hydrochloric Acid SCHEMBL4533102 0.75 ALDH1A1 (0.49) ALDH1A1SMN1; SMN2LMNABLMKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1899296-B1 HISTAMINE-3 RECEPTOR ANTAGONISTS PFIZER PROD INC (US) 2010-11-17 EP disclosed
US-7812040-B2 such as 3-(3-Acetyl-phenyl)-1-[3-(3-chloro-4-pyrrolidin-1-ylmethyl-phenoxy)-cyclobutylmethyl]-1-methyl-urea, used for the treatment of , schizophrenia, Alzheimer's disease, attention-deficit hyperactivity disorder, hypotension, allergies, cardiovascular, gastrointestinal and psychological disorders PFIZER INC. (US) 2010-10-12 US disclosed
US-20090131433-A1 HISTAMINE-3 RECEPTOR ANTAGONISTS PFIZER INC. (US) 2009-05-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131433-A1 HISTAMINE-3 RECEPTOR ANTAGONISTS HRH3, HRH4, HRH2 ALDH1A1 923/4885SMN1; SMN2 2038/4885LMNA 4511/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.